InsiderTrades

Form 4 for BSX Boston Scientific

Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-18 · accession 0001225208-25-001969 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-02-19 2025-02-19 BSX Brennan Daniel J. EVP, CFO M - OptEx $25.61 +60.5K 283.7K +27% +$1.55M
DM 2025-02-19 2025-02-18+ BSX Brennan Daniel J. EVP, CFO S - Sale+OE $105.10 -84.9K 232.6K -27% -$8.92M
DM 2025-02-19 2025-02-19 BSX Brennan Daniel J. EVP, CFO M - OptEx $0.00 -60.5K 31.3K -66% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-19 M A 18,533 $24.55 251,151 D — —
2 Common Common Stock 2025-02-19 S D 67,333 $105.24 225,808 D — — (F4) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3 Common Common Stock 2025-02-19 M A 9,483 $40.12 293,141 D — —
4 Common Common Stock 2025-02-18 S D 2,900 $104.08 247,248 D — — (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
5 Common Common Stock 2025-02-18 S D 14,630 $104.67 232,618 D — — (F3) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
6 Common Common Stock 2025-02-19 M A 16,865 $17.26 268,016 D — —
7 Common Common Stock 2025-02-19 M A 15,642 $27.09 283,658 D — —
8 Derivative Stock Option (Right to Buy) 2025-02-19 M D 9,483 $0.00 37,934 D $40.12 · — to 2029-02-21 9,483 Common Stock (F6) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
9 Derivative Stock Option (Right to Buy) 2025-02-19 M D 16,865 $0.00 0 D $17.26 · — to 2026-02-22 16,865 Common Stock (F7) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
10 Derivative Stock Option (Right to Buy) 2025-02-19 M D 18,533 $0.00 37,067 D $24.55 · — to 2027-02-28 18,533 Common Stock (F8) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
11 Derivative Stock Option (Right to Buy) 2025-02-19 M D 15,642 $0.00 31,285 D $27.09 · — to 2028-02-15 15,642 Common Stock (F5) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.